AI-Designed Drug Rentosertib Shifts Six Aging Clocks in Phase IIa Trial
AIFlow_ML · x · 2026-09-10
- Rentosertib, an AI-designed drug by Insilico Medicine originally developed for idiopathic pulmonary fibrosis (IPF), showed anti-aging effects in a Phase IIa trial.
- Six proteomic "aging clocks" applied to blood samples from 42 participants all detected reductions in predicted biological age, while the placebo group showed little change or slight increases; effects were most pronounced around week 4.
- AI played a dual role: identifying TNIK, an enzyme linked to both fibrosis and aging pathways, and generating/optimizing the inhibiting molecule.
- The study was authored by Insilico with collaborators from Harvard, Stanford, the Broad Institute, RWTH Aachen, Peking University, and Westlake University.
Related event: Insilico's AI-designed drug appears to slow biological aging(2 posts)→
More from Research
- LightMTP: lightweight latent multi-token prediction boosts LLM planning in pretraining — gdm3000 · 2026-10-27
- EMNLP study: AI literary translation reads fine but varies more, even within one book — tuvllms · 2026-10-27
- Lab monkeys at $30-80K each: a 4-year breeding cycle is the real preclinical drug bottleneck — zebird0 · 2026-10-27
- OpenAI Foundation funds UNC tumor antigen project, hiring senior experimental scientist — iskander · 2026-10-27
- Steering attention heads toward honesty: up moral patienthood, down psychopathy — edelwax · 2026-10-27
- Are transcoders overkill? New paper argues plain neurons suffice for circuit analysis — burny_tech · 2026-10-27